Effects of hypoxia/reperfusion injury on drug disposition in the rat isolated perfused liver.
1. Ischaemia-reperfusion injury is known to be associated with a range of functional and structural alterations in the liver. However, the effect of this injury on drug disposition is not well understood. The present study was designed to examine the effects of hypoxia/reperfusion on the disposition of glutamate and propranolol in the rat isolated perfused liver. Both glutamate and propranolol are mainly metabolised in the pericentral region of the liver. 2. Hypoxia/reperfusion was established using the slow flow-reflow method of perfusion in both anterograde and retrograde perfusion. Glutamate metabolism was measured by the recovery of [(14)C]-glutamic acid and [(14)C]-labelled metabolites in a single pass in both anterograde and retrograde perfusion in the presence of a steady state concentration of unlabelled glutamic acid. Propranolol disposition, mean transit time and normalized variance were assessed from the outflow concentration-time profile of unchanged [(3)H]-propranolol determined after a bolus injection of [(3)H]-propranolol using HPLC and liquid scintillation counting. 3. Hypoxia/reperfusion of livers did not affect oxygen consumption, but caused significant changes in enzyme release, lignocaine hepatic availability and bile flow. 4. Hypoxia/reperfusion did not affect the hepatic metabolism of glutamate to carbon dioxide or the hepatic extraction of propranolol. Small but significant changes were evident in the distribution parameters of mean transit time and vascular disposition for the hypoxic-ischaemic liver. 5. It is concluded that reperfusion injury induced by slow flow-reflow perfusion did not influence the extraction of glutamate or propranolol, but may have affected pericentral morphology and solute distribution.
Arab
H A
HA
School of Medicine, University of Queensland, Queensland, Australia.
Cheung
K
K
Hickman
P E
PE
Potter
J M
JM
Kadkhodaee
M
M
Roberts
M S
MS
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics; D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D002245:Carbon Dioxide / Q000378:metabolism; D002250:Carbon Radioisotopes; D005260:Female; D018698:Glutamic Acid / Q000493:pharmacokinetics*; D000860:Hypoxia / Q000503:physiopathology*; D066298:In Vitro Techniques; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008012:Lidocaine / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D010477:Perfusion / Q000379:methods; D011433:Propranolol / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000503:physiopathology*
D000319:Adrenergic beta-Antagonists; D002250:Carbon Radioisotopes; D002245:Carbon Dioxide; D018698:Glutamic Acid; D008012:Lidocaine; D011433:Propranolol; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases